OLMA — Olema Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $614.23m
- $156.16m
Olema Pharmaceuticals Q2 net loss widens on higher clinical trial spending
Brief: Olema Pharmaceuticals Q2 Net Income USD -63.2 Million
Brief: Olema Oncology Announces Clinical Trial Collaboration And Supply Agreement With Bayer To Evaluate Op-3136 In Combination With Nubeqa® (Darolutamide) In Metastatic Castration-Resistant Prostate Cancer
Olema Pharmaceuticals Q1 net loss widens on higher R&D costs
Brief: Olema Pharmaceuticals Q1 Net Income USD -53.089 Million
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
Oncology drug developer Olema Pharmaceuticals' Q4 net loss widens on higher R&D costs
Brief: Olema Oncology Announces Departure Of Chief Operating And Financial Officer
Brief: Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
U.S. STOCKS ON THE MOVE-Viking, Valvoline, Alphabet
U.S. STOCKS ON THE MOVE-Constellation Energy, Williams-Sonoma
U.S. STOCKS ON THE MOVE-Lowe's, TJX Companies, Target
Olema Oncology dips after $190 mln equity offering following stock surge
Brief: Olema Oncology announces pricing of $190 million public offering of common stock
U.S. RESEARCH ROUNDUP- Amgen, Crowdstrike, Micron Technology
Olema Oncology commences equity offering after shares more than double
Brief: Olema Oncology Announces Proposed Public Offering Of Common Stock And Pre-Funded Warrants
Brief: Olema Pharmaceuticals Inc - Terminates ATM Prospectus For Common Stock Dated January 6, 2025 - SEC Filing
Olema Pharma Q3 net loss widens